Vascular bypass

New Engineering Approaches in Vascular Grafts Market Expands Horizon of Endovascular Surgeries, Synthetic Products Attract R&D: TMR

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Medicine, Clinical medicine, Interventional radiology, Stent, Vascular bypass, Atherosclerosis

The drive for improving the clinical outcomes of revascularization solutions has been a key underpinning for the acceptance of vascular grafts .

Key Points: 
  • The drive for improving the clinical outcomes of revascularization solutions has been a key underpinning for the acceptance of vascular grafts .
  • Aim at improving synthetic vascular prostheses is a key force underlying creation of new avenues in the vascular grafts market.
  • Relentless focus on reducing the mortality of vascular diseases is a key accelerant for strides in the vascular grafts market.\nThe global valuation of vascular grafts market in 2017 was US$ 2,010 Mn.
  • Growing preference of stent grafts for treating atherosclerosis is one of the key trends boosting the prospects in the vascular grafts market.

New Engineering Approaches in Vascular Grafts Market Expands Horizon of Endovascular Surgeries, Synthetic Products Attract R&D: TMR

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Medicine, Clinical medicine, Interventional radiology, Stent, Vascular bypass, Atherosclerosis

The drive for improving the clinical outcomes of revascularization solutions has been a key underpinning for the acceptance of vascular grafts .

Key Points: 
  • The drive for improving the clinical outcomes of revascularization solutions has been a key underpinning for the acceptance of vascular grafts .
  • Aim at improving synthetic vascular prostheses is a key force underlying creation of new avenues in the vascular grafts market.
  • Relentless focus on reducing the mortality of vascular diseases is a key accelerant for strides in the vascular grafts market.\nThe global valuation of vascular grafts market in 2017 was US$ 2,010 Mn.
  • Growing preference of stent grafts for treating atherosclerosis is one of the key trends boosting the prospects in the vascular grafts market.

Vascular Graft Solutions Wins FDA approval to Market the VIOLA™ Clampless Proximal Anastomosis System for CABG

Retrieved on: 
Monday, March 1, 2021
Medical specialties, Anatomy, Clinical medicine, Cardiac surgery, Coronary artery bypass surgery, Vascular bypass, Aorta, Ascending aorta, Anastomosis, Off-pump coronary artery bypass, Open aortic surgery

TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG).

Key Points: 
  • TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG).
  • Neurocognitive dysfunction remains the most devastating perioperative complication of CABG and frequently attributed to atheroembolism that originate from the ascending aorta.
  • The VIOLA device minimizes aortic manipulation during on and off-pump CABG and enable cardiac surgeons to perform protected, clean, and dry proximal anastomosis without partial clamping the aorta.
  • VIOLA is a new generation of clampless proximal anastomosis system that combines a standard punching mechanism with optimal sealing during anastomosis construction.

Marizyme Announces Approval for DuraGraft® in India

Retrieved on: 
Thursday, January 14, 2021
Neurosurgery, Vascular bypass

India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.

Key Points: 
  • India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.
  • Dr. Neil Campbell, Marizyme, Inc. President and CEO, said, "We are excited to receive this approval in India and to be working with Regency Lifesciences to bring the healthcare professionals and patients of India this first in class product.
  • India joins a growing list of countries that will form the basis of our commercial efforts in 2021 for DuraGraft."
  • Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com .

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Clinical medicine, Medicine, Cardiac surgery, Coronary artery bypass surgery, Vascular surgery, Aging-associated diseases, Revascularization, Vascular bypass, Myocardial infarction, Ischemia, Vein graft failure

DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.

Key Points: 
  • DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.
  • The use of DuraGraft is associated with the reduction of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization, and MACE.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Clinical medicine, Medicine, Cardiac surgery, Coronary artery bypass surgery, Vascular surgery, Aging-associated diseases, Revascularization, Vascular bypass, Myocardial infarction, Ischemia, Vein graft failure

DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.

Key Points: 
  • DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.
  • The use of DuraGraft is associated with the reduction of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization, and MACE.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

North America Aortic and Vascular Graft Procedures Outlook to 2025 - Aortic Stent Graft Procedures and Vascular Grafts Procedures

Retrieved on: 
Tuesday, December 1, 2020
Medical specialties, Medicine, Surgery, Interventional radiology, Vascular surgery, Stent, Vascular bypass, Cardiac surgery, Endovascular aneurysm repair, Draft:Nicolai L. Volodos

"North America Aortic and Vascular Graft Procedures Outlook to 2025" is a comprehensive databook report, covering key procedures data on the North America Aortic and Vascular Graft Procedures.

Key Points: 
  • "North America Aortic and Vascular Graft Procedures Outlook to 2025" is a comprehensive databook report, covering key procedures data on the North America Aortic and Vascular Graft Procedures.
  • The databook report provides procedure volumes within segments - Aortic Stent Graft Procedures and Vascular Grafts Procedures.
  • - Procedure volume data for Aortic and Vascular Graft Procedures related to the country.
  • Data is provided from 2015 to 2025.

Vascular Grafts Pipeline Insight and Competitive Landscape, 2020 Report - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Chemicals, Plastics, Manufacturing, Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Surgery, Neurosurgery, Vascular bypass, Aneurysm, Graft

The "Vascular Grafts Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Grafts Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Vascular Grafts - Pipeline Insight and Competitive Landscape, 2020, report provides comprehensive insights on 20+ companies and 25+ pipeline devices in Vascular Grafts pipeline landscape.
  • Vascular Grafts can be divided based on raw materials - Polyester Grafts, ePTFE, Polyurethane Grafts and Biosynthetic Grafts, which are covered in the report.
  • Vascular Grafts can be divided based on its application - Cardiac Aneurysms, Vascular Occlusion and Kidney Failure, which are covered in the report.

China National Medical Products Administration (NMPA) Grants Innovative Medical Device Designation for VEST in China

Retrieved on: 
Thursday, October 1, 2020
Medicine, Interventional radiology, Neurosurgery, Vascular bypass, Stent, Coronary artery bypass surgery

TEL AVIV, Israel, Oct. 1,2020 /PRNewswire/ --Vascular Graft Solutions Ltd. (VGS), an Israel-based innovative commercial-stage medical device company, announced today that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation for VEST, an external stent for vein grafts in coronary artery bypass surgery.

Key Points: 
  • TEL AVIV, Israel, Oct. 1,2020 /PRNewswire/ --Vascular Graft Solutions Ltd. (VGS), an Israel-based innovative commercial-stage medical device company, announced today that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation for VEST, an external stent for vein grafts in coronary artery bypass surgery.
  • "We are excited that VEST has been granted the Innovative Device Designation," said Eyal Orion, M.D., founder, and CEO of VGS.
  • "Only one out of five medical devices granted innovative device status by NMPA in 2019, of which only 20% were of overseas companies.
  • The innovative medical device designation provides a support platform for the assigned technologies to enter the Chinese market.

Global Vascular Injury Treatment Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 17, 2020
Hospitals, General Health, Health, Cardiology, RTT, Aging-associated diseases, Coronary artery disease, Medical specialties, Cardiovascular disease, Clinical medicine, Medicine, Cardiovascular disease in Australia, Vascular bypass

As per the National Institutes of Health (NIH), about 14 million men and women across the country are affected by coronary heart disease.

Key Points: 
  • As per the National Institutes of Health (NIH), about 14 million men and women across the country are affected by coronary heart disease.
  • Bypass graft is the most common treatment for vascular injury to improve poor blood flow to the heart.
  • North America is expected to maintain its supremacy in the overall vascular injury treatment market, throughout the forecast period.
  • The increasing prevalence of vascular diseases is the major factor expected to drive the overall growth of the market, during the forecast period.